NASDAQ:MTP - Midatech Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.7538 0.00 (0.00 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$0.7538
Today's Range$0.73 - $0.83
52-Week Range$0.66 - $3.27
Volume95,183 shs
Average Volume462,014 shs
Market Capitalization$23.02 million
P/E Ratio-1.03
Dividend YieldN/A
Beta0.87

About Midatech Pharma (NASDAQ:MTP)

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. The company also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy. In addition, it is involved in the research and development of various product candidates in the areas of oncology and neuroscience, including ophthalmology; and immunotherapy. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.

Receive MTP News and Ratings via Email

Sign-up to receive the latest news and ratings for MTP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MTP
CUSIPN/A
Phone44-0-12-3588-8300

Debt

Debt-to-Equity Ratio0.18
Current Ratio2.22
Quick Ratio2.11

Price-To-Earnings

Trailing P/E Ratio-1.03
Forward P/E Ratio-2.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.79 million
Price / Sales2.35
Cash FlowN/A
Price / CashN/A
Book Value$1.46 per share
Price / Book0.52

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees79
Outstanding Shares30,540,000

Midatech Pharma (NASDAQ:MTP) Frequently Asked Questions

What is Midatech Pharma's stock symbol?

Midatech Pharma trades on the NASDAQ under the ticker symbol "MTP."

When is Midatech Pharma's next earnings date?

Midatech Pharma is scheduled to release their next quarterly earnings announcement on Monday, July, 23rd 2018. View Earnings Estimates for Midatech Pharma.

Who are some of Midatech Pharma's key competitors?

Who are Midatech Pharma's key executives?

Midatech Pharma's management team includes the folowing people:
  • Dr. James Neil Phillips, Chief Exec. Officer & Director (Age 56)
  • Mr. Nicholas John Robbins-Cherry, CFO, Company Sec. & Director (Age 49)
  • Dr. Craig Cook, Chief Operating Officer (Age 51)
  • Dr. Dan Palmer Ph.D., MBA, Chief Scientific Officer
  • Mr. Rob Rainey FCA MBA MA, Head of Corp. Devel.

Has Midatech Pharma been receiving favorable news coverage?

News stories about MTP stock have trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Midatech Pharma earned a media sentiment score of 0.08 on Accern's scale. They also assigned media coverage about the company an impact score of 46.31 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Midatech Pharma?

Shares of MTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Midatech Pharma's stock price today?

One share of MTP stock can currently be purchased for approximately $0.7538.

How big of a company is Midatech Pharma?

Midatech Pharma has a market capitalization of $23.02 million and generates $9.79 million in revenue each year. The company earns $-20,700,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Midatech Pharma employs 79 workers across the globe.

How can I contact Midatech Pharma?

Midatech Pharma's mailing address is 65 INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RQ. The company can be reached via phone at 44-0-12-3588-8300 or via email at [email protected]


MarketBeat Community Rating for Midatech Pharma (MTP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Midatech Pharma and other stocks. Vote "Outperform" if you believe MTP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Midatech Pharma (NASDAQ:MTP) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/27/2016 forward)

Earnings

Dividends

Midatech Pharma (NASDAQ:MTP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Midatech Pharma (NASDAQ MTP) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.32%
Insider Trading History for Midatech Pharma (NASDAQ:MTP)

Midatech Pharma (NASDAQ MTP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Midatech Pharma (NASDAQ MTP) News Headlines

Source:
DateHeadline
Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancerMidatech commences US clinical study of its investigational treatment for fatal childhood brain cancer
finance.yahoo.com - May 25 at 9:54 AM
Midatech Pharma (MTP) Raised to "Hold" at ValuEngineMidatech Pharma (MTP) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - May 2 at 11:37 PM
MTP: Midatech Targeting $2 Billion Market Opportunity with MTD201MTP: Midatech Targeting $2 Billion Market Opportunity with MTD201
finance.yahoo.com - April 27 at 10:40 AM
Where Münchener Tierpark Hellabrunn AG’s (MUN:MTP) Earnings Growth Stands Against Its IndustryWhere Münchener Tierpark Hellabrunn AG’s (MUN:MTP) Earnings Growth Stands Against Its Industry
finance.yahoo.com - March 23 at 9:59 AM
New chief at MidtechNew chief at Midtech
seekingalpha.com - March 16 at 10:39 AM
Midatech announces changes in Senior Management TeamMidatech announces changes in Senior Management Team
finance.yahoo.com - March 15 at 10:04 AM
FY2017 EPS Estimates for Midatech Pharma PLC-ADR Decreased by Zacks Investment Research (MTP)FY2017 EPS Estimates for Midatech Pharma PLC-ADR Decreased by Zacks Investment Research (MTP)
www.americanbankingnews.com - March 12 at 1:17 AM
MTP: Lead Candidates Set to Enter the Clinic; U.S. Product Sales Up ~30% in 2017MTP: Lead Candidates Set to Enter the Clinic; U.S. Product Sales Up ~30% in 2017
finance.yahoo.com - March 7 at 10:20 AM
MTP: Receives Approval to Initiate First In Human Trial of Q-Octreotide (MTD201); Four Year Loan Agreement with MidCap FinancialMTP: Receives Approval to Initiate First In Human Trial of Q-Octreotide (MTD201); Four Year Loan Agreement with MidCap Financial
finance.yahoo.com - January 12 at 4:54 PM
European ADRs Move Lower in Tuesday TradingEuropean ADRs Move Lower in Tuesday Trading
www.nasdaq.com - January 10 at 9:54 AM
European ADRs Move Lower in Wednesday TradingEuropean ADRs Move Lower in Wednesday Trading
www.nasdaq.com - January 4 at 5:04 PM
Europe ADRs Decline in Wednesday SessionEurope ADRs Decline in Wednesday Session
www.nasdaq.com - December 22 at 9:57 AM
European ADRs Move Higher in Tuesday TradingEuropean ADRs Move Higher in Tuesday Trading
www.nasdaq.com - December 12 at 5:26 PM
European ADRs Advance as Banks Log GainsEuropean ADRs Advance as Banks Log Gains
www.nasdaq.com - December 9 at 9:50 AM
Midatech Pharma PLC (MTP) to Post Q3 2017 Earnings of ($0.08) Per Share, Zacks Investment Research ForecastsMidatech Pharma PLC (MTP) to Post Q3 2017 Earnings of ($0.08) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - November 30 at 5:58 AM
Initiating Coverage of Midatech Pharma (MTP); Novel Nanotechnology Platforms Focused on Oncology and Other Therapeutic AreasInitiating Coverage of Midatech Pharma (MTP); Novel Nanotechnology Platforms Focused on Oncology and Other Therapeutic Areas
finance.yahoo.com - November 27 at 4:53 PM
Midatech Pharma Plc: Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegalyMidatech Pharma Plc: Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly
feeds.benzinga.com - September 4 at 7:55 AM
European ADRs Fractionally Higher Despite Banking ContractionsEuropean ADRs Fractionally Higher Despite Banking Contractions
www.nasdaq.com - June 1 at 7:33 PM
European ADRs Fractionally Higher as Banking Stocks Edge ForwardEuropean ADRs Fractionally Higher as Banking Stocks Edge Forward
www.nasdaq.com - May 1 at 5:40 PM
European ADRs Fractionally Higher as Banking Stocks Edge ForwardEuropean ADRs Fractionally Higher as Banking Stocks Edge Forward
www.nasdaq.com - May 1 at 5:40 PM
European ADRs Edge Higher as Pharmaceutical Stocks See Mixed FortunesEuropean ADRs Edge Higher as Pharmaceutical Stocks See Mixed Fortunes
www.nasdaq.com - April 18 at 10:16 AM
European ADRs Edge Lower as Telecommunication Stocks Head SouthEuropean ADRs Edge Lower as Telecommunication Stocks Head South
www.nasdaq.com - April 3 at 5:58 PM
European ADRs Fractionally Higher as Pharmaceutical Stocks See Mixed FortunesEuropean ADRs Fractionally Higher as Pharmaceutical Stocks See Mixed Fortunes
www.nasdaq.com - March 28 at 10:15 AM
European ADRs Edge Lower as Manufacturers Head SouthEuropean ADRs Edge Lower as Manufacturers Head South
www.nasdaq.com - March 24 at 11:42 PM
7:42 am Midatech Pharma announces the successful initial scale-up and regulatory inspection of its state-of-the-art manufacturing site in Bilbao, Spain7:42 am Midatech Pharma announces the successful initial scale-up and regulatory inspection of its state-of-the-art manufacturing site in Bilbao, Spain
us.rd.yahoo.com - March 10 at 9:40 AM
European ADRs Fractionally Lower as Miners Head SouthEuropean ADRs Fractionally Lower as Miners Head South
www.nasdaq.com - March 9 at 8:33 AM
European ADRs Fractionally Lower Despite Banking GainsEuropean ADRs Fractionally Lower Despite Banking Gains
www.nasdaq.com - January 19 at 10:09 PM
European ADRs Move Higher in Thursday TradingEuropean ADRs Move Higher in Thursday Trading
www.nasdaq.com - December 29 at 6:40 PM
European ADRs Fractionally Higher as Pharma Stocks Gains Offset Mining LossesEuropean ADRs Fractionally Higher as Pharma Stocks' Gains Offset Mining Losses
www.nasdaq.com - December 23 at 11:52 PM
European ADRs Advance as Telecommunication Stocks Gain TractionEuropean ADRs Advance as Telecommunication Stocks Gain Traction
www.nasdaq.com - December 16 at 7:22 PM
European ADRs Rally as Telecommunications Stocks AdvanceEuropean ADRs Rally as Telecommunications Stocks Advance
www.nasdaq.com - December 13 at 7:05 PM

SEC Filings

Midatech Pharma (NASDAQ:MTP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Midatech Pharma (NASDAQ:MTP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Midatech Pharma (NASDAQ MTP) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.